



## King's Research Portal

DOI:

[10.1002/wps.20522](https://doi.org/10.1002/wps.20522)

*Document Version*

Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Howes, O. D., & Kaar, S. J. (2018). Antipsychotic drugs: challenges and future directions. *World Psychiatry*, 17(2), 170-171. <https://doi.org/10.1002/wps.20522>

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

## Antipsychotic drugs: challenges and future directions

Some sixty years on from the first use of chlorpromazine to treat schizophrenia, it is worth reflecting on where we have come from. Back in the 1950s it was not known that dopamine was a neurotransmitter, how antipsychotics worked, what symptoms they worked on, or indeed if they worked at all<sup>1</sup>. Now we know that dopamine is a neurotransmitter, antipsychotics are all dopamine receptor blockers and, as Correll et al<sup>2</sup> nicely review, large randomized, double-blind placebo-controlled trials have unequivocally demonstrated that they work both to treat acute psychotic episodes and to reduce relapse rates over the short to medium term.

Recent meta-analytic data generated from over sixty years of placebo-controlled trials estimate the standardized mean difference (SMD) between antipsychotics and placebo to be 0.38, with a greater effect seen on positive symptoms (SMD=0.45) than negative symptoms (SMD=0.35), quality of life (SMD=0.35) or depression (SMD=0.27)<sup>3</sup>. Such effect sizes are comparable to or larger than those found for treatments used for many common physical health conditions, including angiotensin-converting enzyme (ACE) inhibitors for reducing cardiac events and mortality due to hypertension (SMD=0.16) and statins for reducing the risk of cardiac disease and stroke (SMD=0.15)<sup>4</sup>. Clearly, we have come a long way from the 1950s, but, despite these robust data on antipsychotics, many fundamental gaps in knowledge remain.

One glaring gap highlighted in this Forum is that as of yet we are unable to say conclusively what the optimum length of treatment with antipsychotic medication should be, once a patient has recovered from an acute episode. In current practice, many patients are treated with antipsychotic medication long-term if not lifelong, in an attempt to prevent the frequency and severity of relapses that can be so disruptive to a person's life.

Where patients are symptom free but experiencing side-effects such as a weight gain that may shorten life as well as affect its quality, the risk-benefit balance for relapse prevention is finely poised. Yet, as Correll et al highlight, there is little evidence from randomized, double blind controlled studies to support prophylactic treatment beyond two-three years. Whilst some naturalistic studies do provide support for treatment beyond this term, the inherent limitations of these designs mean that the question remains unresolved, and guidelines cannot be conclusive.

This is a challenge to the field which needs to be met. We will need longer and, crucially, larger randomized controlled studies. This will not be easy, but other fields have risen to the challenge. For example, in the case of the examples discussed above, statins and ACE inhibitors, there are now a number of randomized placebo-controlled trials with several thousand patients. These studies are roughly two orders of magnitude larger and five to ten times longer than the typical long-term randomized controlled study in schizophrenia. These large sample sizes give the power to have extended follow-up and account for treatment changes and drop-out. It is likely that we will need new ways of working, including international academic consortia as well as partnership with the pharmaceutical industry and governments, to achieve such large-scale studies.

Correll et al also highlight heterogeneity in schizophrenia, something that is increasingly becoming apparent in the neurobiology underlying the disorder as well as its clinical manifestations, course and treatment response<sup>5</sup>.

Treatment resistance is probably the most clinically important manifestation of heterogeneity in patients with schizophrenia, and remains a major issue that continues to provoke debate over its pathophysiology, diagnosis and clinical management<sup>6</sup>. About a third of patients are thought to have treatment resistant illnesses, and around 15% show treatment resistance from illness onset<sup>7</sup>. Moreover, we have no way to identify the individuals whose illness will benefit from antipsychotic treatment.

Thus, currently large numbers of patients receive antipsychotic treatment although their illness is unlikely to respond to dopamine antagonists. The solutions to this will likely be found

in part through identifying biomarkers that allow disease stratification, for example by the likelihood of response to dopamine receptor antagonists and, in the future, novel non-dopamine receptor blocking medication.

As both trial data and clinical experience show, current antipsychotic treatment works most effectively in reducing the positive symptoms of schizophrenia, whereas the negative and cognitive symptoms often remain problematic. Cognitive symptoms in particular are associated with poor functional outcomes in schizophrenia<sup>8</sup>, yet our current treatments do little for them. In fact, there is evidence to suggest that dopamine antagonists may cause secondary negative and cognitive symptoms in people with schizophrenia<sup>9</sup>. Put simply, taking an antipsychotic may be unpleasant for some patients, and lead to secondary symptoms. This highlights the third challenge to the field: the need to develop treatments that are more than just antipsychotic and that patients are happy to take in the long term if necessary.

The final challenge is that our current antipsychotic medications are not disease modifying. Pre-synaptic striatal dopamine dysfunction is thought to drive the symptoms of schizophrenia<sup>10</sup>, yet all of our current antipsychotic drugs act post-synaptically. Thus, they block the consequences of pre-synaptic dopamine dysfunction but do not address the underlying dopamine dysfunction, which remains present even after long-term treatment. This provides a neurobiological explanation for why patients may relapse on stopping antipsychotic treatment.

Targeting the upstream abnormality and/or the factors that lead to it is an alternative approach that could both be better tolerated and more effective in the long term. Broadly speaking, the glutamatergic and GABAergic systems have excitatory and inhibitory effects, respectively, on the dopamine system. Genetic studies measuring copy number variants in patients with schizophrenia<sup>11</sup> suggest that abnormalities in both neurotransmitter systems may be critical to the upstream regulation of dopamine. Findings like these suggest that targeting GABA and glutamate control of subcortical dopamine function could modify the pathophysiology, and potentially even be disease modifying. The interaction between psychosocial factors and biological changes<sup>12</sup> also highlights the potential for psychological treatments to be disease modifying.

It is clear that we have come a long way from the 1950s in terms of both understanding of the pathophysiology of schizophrenia and its treatment, and this has thrown up new questions and issues. Antipsychotic drugs are likely to remain a crucial part of our therapeutic arsenal for years to come, so it behoves us to address the questions that remain.

Oliver D. Howes<sup>1-3</sup>, Stephen J. Kaar<sup>1</sup>

Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; <sup>2</sup>Medical Research Council London Institute of Medical Sciences, London, UK; <sup>3</sup>Institute of Clinical Sciences, Imperial College, Hammersmith Hospital Campus, London, UK

1. Howes O, McCutcheon R, Stone J. *J Psychopharmacol* 2015;29:97-115.
2. Correll CU, Rubio JM, Kane JM. *World Psychiatry* 2018;17: .
3. Leucht S, Leucht C, Huhn M et al. *Am J Psychiatry* 2017;174:927-42.
4. Leucht S, Hierl S, Kissling W, et al. *BJPsych* 2012; 200(2): 97-106.
5. Brugger SP, Howes OD. *JAMA Psychiatry* 2017;74:1104-11.
6. Howes OD, McCutcheon R, Agid O et al. *Am J Psychiatry* 2016;174:216-29.
7. Lally J, Ajnakina O, Di Forti M et al. *Psychol Med* 2016;46:3231-40.
8. Green MF. *J Clin Psychiatry* 2016;77(Suppl. 2):8-11.
9. Kirschner M, Aleman A, Kaiser S. *Schizophr Res* 2017;186:29-38.
10. Demjaha A, Murray RM, McGuire PK et al. *Am J Psychiatry* 2012;169:1203-10.
11. Pocklington AJ, Rees E, Walters JT et al. *Neuron* 2015;86:1203-14.
12. Howes OD, Murray RM. *Lancet* 2014;383:1677-87.